{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T11:24:29Z","timestamp":1769599469059,"version":"3.49.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2006,3,1]]},"DOI":"10.1093\/carcin\/bgi233","type":"journal-article","created":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:24:29Z","timestamp":1128126269000},"page":"568-577","source":"Crossref","is-referenced-by-count":33,"title":["N-(4-Hydroxyphenyl)retinamide and nitric oxide pro-drugs exhibit apoptotic and anti-invasive effects against bone metastatic breast cancer cells"],"prefix":"10.1093","volume":"27","author":[{"given":"Ann-Marie","family":"Simeone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Colella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Krahe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcella M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edna","family":"Mora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana M.","family":"Tari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,9,30]]},"reference":[{"key":"key\n\t\t\t\t20171012210115_B1","doi-asserted-by":"crossref","unstructured":"Coleman,R.E. and Rubens,R.D. (\n            1987\n            ) The clinical course of bone metastases from breast cancer. \n            Br. J. Cancer\n            , \n            55\n            , \n            61\n            \u201366.","DOI":"10.1038\/bjc.1987.13"},{"key":"key\n\t\t\t\t20171012210115_B2","doi-asserted-by":"crossref","unstructured":"Aaron,A.D. (\n            1994\n            ) The management of cancer metastatic to bone. \n            JAMA\n            , \n            272\n            , \n            1206\n            \u20131209.","DOI":"10.1001\/jama.1994.03520150074040"},{"key":"key\n\t\t\t\t20171012210115_B3","doi-asserted-by":"crossref","unstructured":"Weiss,L. (\n            1992\n            ) Comments on hematogenous metastatic patterns in humans as revealed by autopsy. \n            Clin. Exp. Metastasis\n            , \n            10\n            , \n            191\n            \u2013199.","DOI":"10.1007\/BF00132751"},{"key":"key\n\t\t\t\t20171012210115_B4","doi-asserted-by":"crossref","unstructured":"Gauthier,N., Lohm,S., Touzery,C., Chantome,A., Perette,B., Reveneau,S., Brunotte,F., Juillerat-Jeanneret,L. and Jeannin,J.-F. (\n            2004\n            ) Tumour-derived and host-derived nitric oxide differentially regulate breast carcinoma metastasis to the lungs. \n            Carcinogenesis\n            , \n            25\n            , \n            1559\n            \u20131565.","DOI":"10.1093\/carcin\/bgh158"},{"key":"key\n\t\t\t\t20171012210115_B5","doi-asserted-by":"crossref","unstructured":"Thomsen,L.L., Miles,D.W., Happerfield,L., Bobrow,L.G., Knowles,R.G. and Moncada,S. (\n            1995\n            ) Nitric oxide synthase activity in human breast cancer. \n            Br. J. Cancer\n            , \n            72\n            , \n            41\n            \u201344.","DOI":"10.1038\/bjc.1995.274"},{"key":"key\n\t\t\t\t20171012210115_B6","doi-asserted-by":"crossref","unstructured":"Tschugguel,W., Schneeberger,C., Unfried,G., Czerwenka,K., Weninger,W., Mildner,M., Gruber,D.M., Sator,M.O., Waldhor,T. and Huber,J.C. (\n            1999\n            ) Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade. \n            Breast Cancer Res. Treat.\n            , \n            56\n            , \n            145\n            \u2013151.","DOI":"10.1023\/A:1006288526311"},{"key":"key\n\t\t\t\t20171012210115_B7","unstructured":"Vakkala,M., Kahlos,K., Lakari,E., Paakko,P., Kinnula,V. and Soini,Y. Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in \n            in situ\n             and invasive breast carcinomas. \n            Clin. Cancer Res.\n            , \n            6\n            , \n            2408\n            \u20132416."},{"key":"key\n\t\t\t\t20171012210115_B8","doi-asserted-by":"crossref","unstructured":"Xu,W., Liu,L., Smith,G.C. and Charles,G. (\n            2000\n            ) Nitric oxide upregulates expression of DNA-PKcs to protect cells from DNA-damaging anti-tumour agents. \n            Nat. Cell Biol.\n            , \n            2\n            , \n            339\n            \u2013345.","DOI":"10.1038\/35010529"},{"key":"key\n\t\t\t\t20171012210115_B9","doi-asserted-by":"crossref","unstructured":"Orucevic,A., Bechberger,J., Green,A.M., Shapiro,R.A., Billiar,T.R. and Lala,P.K. (\n            1999\n            ) Nitric-oxide production by murine mammary adenocarcinoma cells promotes tumor-cell invasiveness. \n            Int. J. Cancer\n            , \n            81\n            , \n            889\n            \u2013896.","DOI":"10.1002\/(SICI)1097-0215(19990611)81:6<889::AID-IJC9>3.0.CO;2-2"},{"key":"key\n\t\t\t\t20171012210115_B10","doi-asserted-by":"crossref","unstructured":"Jadeski,L.C., Hum,K.O., Chakraborty,C. and Lala,P.K. (\n            2000\n            ) Nitric oxide promotes mammary tumor growth and metastasis by stimulating tumour cell migration, invasiveness and angiogenesis. \n            Int. J. Cancer\n            , \n            86\n            , \n            30\n            \u201339.","DOI":"10.1002\/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I"},{"key":"key\n\t\t\t\t20171012210115_B11","unstructured":"Bani,D., Mansini,E., Bello,M.G., Bigazzi,M. and Sacchi,T.B. (\n            1995\n            ) Relaxin activates the L-arginine-nitric oxide pathway in human breast cancer cells. \n            Cancer Res.\n            , \n            55\n            , \n            5272\n            \u20135275."},{"key":"key\n\t\t\t\t20171012210115_B12","doi-asserted-by":"crossref","unstructured":"Adami,A., Crivellente,F., De Prati,A.C., Cabalieri,E., Cuzzolin,L., Tommasi,M., Suzuki,H. and Benoni,G. (\n            1998\n            ) Biotransformation and cytotoxic properties of NO-donors on MCF7 and U251 cell lines. \n            Life Sci.\n            , \n            63\n            , \n            2097\n            \u20132105.","DOI":"10.1016\/S0024-3205(99)80006-X"},{"key":"key\n\t\t\t\t20171012210115_B13","unstructured":"Binder,C., Schulz,M., Hiddemann,W. and Oellerich,M. (\n            1999\n            ) Induction of inducible nitric oxide synthase is an essential part of tumor necrosis factor-(-induced apoptosis in MCF-7 and other epithelial tumor cells. \n            Lab. Invest.\n            , \n            79\n            , \n            1703\n            \u20131712."},{"key":"key\n\t\t\t\t20171012210115_B14","doi-asserted-by":"crossref","unstructured":"Umansky,V., Ushmorov,A., Ratter,F., Chlichlia,K., Bucur,M., Lichtenauer,A. and Rocha,M. (\n            2000\n            ) Nitric oxide-mediated apoptosis in human breast cancer cells requires changes in mitochondrial functions and is independent of CD95(APO-1\/Fas). \n            Int. J. Oncol.\n            , \n            16\n            , \n            109\n            \u2013117.","DOI":"10.3892\/ijo.16.1.109"},{"key":"key\n\t\t\t\t20171012210115_B15","unstructured":"Simeone,A., Ekmekcioglu,S., Broemeling,L.D., Grimm,E.A. and Tari,A.M. (\n            2002\n            ) A novel mechanism by which N-(4-hydroxyphenyl)retinamide inhibits breast cancer cell growth: the production of nitric oxide. \n            Mol. Cancer Ther.\n            , \n            1\n            , \n            1009\n            \u20131017."},{"key":"key\n\t\t\t\t20171012210115_B16","doi-asserted-by":"crossref","unstructured":"Hussain,S.P., Hofseth,L.J. and Harris,C.C. (\n            2003\n            ) Radical causes of cancer. \n            Nat. Rev. Cancer\n            , \n            3\n            , \n            276\n            \u2013285.","DOI":"10.1038\/nrc1046"},{"key":"key\n\t\t\t\t20171012210115_B17","unstructured":"Dong,Z., Staroselsky,A.H., Qi,X., Xie,K. and Fidler,I.J. (\n            1994\n            ) Inverse correlation between expression of inducible nitric oxide synthase activity and production metastasis in K-1735 murine melanoma cells. \n            Cancer Res.\n            , \n            54\n            , \n            789\n            \u2013793."},{"key":"key\n\t\t\t\t20171012210115_B18","unstructured":"Dhar,A., Brindley,J.M., Stark,C., Citro,M.L., Keefer,L.K. and Colburn,N.H. (\n            2003\n            ) Nitric oxide does not mediate but inhibits transformation and tumor phenotype. \n            Mol. Cancer Ther.\n            , \n            2\n            , \n            1285\n            \u20131293."},{"key":"key\n\t\t\t\t20171012210115_B19","doi-asserted-by":"crossref","unstructured":"Le,X., Wei,D., Huang,S., Lancaster,J.R. and Xie,K. (\n            2005\n            ) Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its upregulation of protumor factors. \n            Proc. Natl Acad. Sci. USA\n            , \n            102\n            , \n            8758\n            \u20138763.","DOI":"10.1073\/pnas.0409581102"},{"key":"key\n\t\t\t\t20171012210115_B20","doi-asserted-by":"crossref","unstructured":"Um,S.-J., Lee,S.-Y., Kim,E.-J., Han,H.-S., Koh,Y.-M., Hong,K.-J., Sin,H.-S. and Park,J.-S. (\n            2001\n            ) Antiproliferative mechanism of retinoid derivatives in ovarian cancer cells. \n            Cancer Lett.\n            , \n            174\n            , \n            127\n            \u2013134.","DOI":"10.1016\/S0304-3835(01)00697-8"},{"key":"key\n\t\t\t\t20171012210115_B21","unstructured":"Kim,J.H., Tanabe,T., Chodak,G.W. and Rukstalis,D.B. (\n            1995\n            ) \n            In vitro\n             anti-invasive effects of N-(4-hydroxyphenyl)-retinamide on human prostatic adenocarcinoma. \n            Anticancer Res.\n            , \n            15\n            , \n            1429\n            \u20131434."},{"key":"key\n\t\t\t\t20171012210115_B22","doi-asserted-by":"crossref","unstructured":"Webber,M.M., Bello-DeOcampo,D., Quader,S., Deocampo,N.D., Metcalfe,W.S. and Sharp,R.M. (\n            1999\n            ) Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR). \n            Clin. Exp. Metastasis\n            , \n            17\n            , \n            255\n            \u2013263.","DOI":"10.1023\/A:1006665616932"},{"key":"key\n\t\t\t\t20171012210115_B23","doi-asserted-by":"crossref","unstructured":"Quader,S.T.A., Bello-DeOcampo,D., Williams,D.E., Kleinman,H.K. and Webber,M.M. (\n            2001\n            ) Evaluation of the chemopreventive potential of retinoids using a novel \n            in vitro\n             human prostate carcinogenesis model. \n            Mutat. Res.\n            , \n            496\n            , \n            153\n            \u2013161.","DOI":"10.1016\/S1383-5718(01)00230-3"},{"key":"key\n\t\t\t\t20171012210115_B24","doi-asserted-by":"crossref","unstructured":"Sharp,R.M., Bello-DeOcampo,D., Quader,S.T.A. and Webber,M.M. (\n            2001\n            ) N-(4-hydroxyphenyl)retinamide (4-HPR) decreases neoplastic properties of human prostate cells: an agent for prevention. \n            Mutat. Res.\n            , \n            496\n            , \n            163\n            \u2013170.","DOI":"10.1016\/S1383-5718(01)00231-5"},{"key":"key\n\t\t\t\t20171012210115_B25","unstructured":"Ferrari,N., Morini,M., Pfeffer,U., Minghelli,S., Noonan,D.M. and Albini,A. (\n            2003\n            ) Inhibition of Kaposi's sarcoma \n            in vivo\n             by fenretinide. \n            Clin. Cancer Res.\n            , \n            9\n            , \n            6020\n            \u20136029."},{"key":"key\n\t\t\t\t20171012210115_B26","doi-asserted-by":"crossref","unstructured":"Saavedra,J.E., Shami,P.J., Wang,L.Y., Davies,K.M., Booth,M.N., Citro,M.L. and Keefer,L.K. (\n            2000\n            ) Esterase-sensitive nitric oxide donors of the diazeniumdiolate family. \n            In vitro\n             antileukemic activity. \n            J. Med. Chem.\n            , \n            43\n            , \n            261\n            \u2013269.","DOI":"10.1021\/jm9903850"},{"key":"key\n\t\t\t\t20171012210115_B27","doi-asserted-by":"crossref","unstructured":"Brunner,N., Thompson,E.W., Spang-Thomsem,M., Rygaard,J., Dano,K. and Zwiebel,J.A. (\n            1992\n            ) lacZ transduced human breast cancer xenografts as an \n            in vivo\n             model for the study of invasion and metastasis. \n            Eur. J. Cancer\n            , \n            28A\n            , \n            1989\n            \u20131995.","DOI":"10.1016\/0959-8049(92)90245-W"},{"key":"key\n\t\t\t\t20171012210115_B28","doi-asserted-by":"crossref","unstructured":"Yoneda,T., Williams,P.J., Hiraga,T., Niewolna,M. and Nishimura,R. (\n            2001\n            ) A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone \n            in vivo\n             and \n            in vitro\n            . \n            J. Bone Min. Res.\n            , \n            16\n            , \n            1486\n            \u20131495.","DOI":"10.1359\/jbmr.2001.16.8.1486"},{"key":"key\n\t\t\t\t20171012210115_B29","doi-asserted-by":"crossref","unstructured":"Formelli,F., Clerici,M., Campa,T., Di Mauro,M., Magni,A., Mascotti,G., Moglia,D., De Palo,G., Costa,A. and Veronesi,U. (\n            1993\n            ) Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. \n            J. Clin. Oncol.\n            , \n            11\n            , \n            2036\n            \u20132042.","DOI":"10.1200\/JCO.1993.11.10.2036"},{"key":"key\n\t\t\t\t20171012210115_B30","doi-asserted-by":"crossref","unstructured":"Hagemann,T., Robinson,S.C., Schulz,M., Trumper,L., Balkwill,F.R. and Binder,C. (\n            2004\n            ) Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent upregulation of matrix metalloproteases. \n            Carcinogenesis\n            , \n            25\n            , \n            1543\n            \u20131549.","DOI":"10.1093\/carcin\/bgh146"},{"key":"key\n\t\t\t\t20171012210115_B31","doi-asserted-by":"crossref","unstructured":"Simeone,A., Broemeling,L.D., Rosenblum,J. and Tari,A.M. (\n            2003\n            ) HER2\/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production. \n            Oncogene\n            , \n            22\n            , \n            6739\n            \u20136747.","DOI":"10.1038\/sj.onc.1206786"},{"key":"key\n\t\t\t\t20171012210115_B32","doi-asserted-by":"crossref","unstructured":"Balduyck,M., Zerimach,F., Gouyer,V. \n            et al\n            . (\n            2000\n            ) Specific expression of matrix metalloproteases 1, 3, 9 and 13 associated with invasiveness of breast cancer cells in vitro. \n            Clin. Exp. Metastasis\n            , \n            18\n            , \n            171\n            \u2013178.","DOI":"10.1023\/A:1006762425323"},{"key":"key\n\t\t\t\t20171012210115_B33","doi-asserted-by":"crossref","unstructured":"Morini,M., Mottolese,M., Ferrari,N., Ghiorzo,F., Buglioni,S., Mortarini,R., Noonan,D.M., Natali,P.G. and Albini,A. (\n            2000\n            ) The alpha 3 beta 1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (MMP-9) activity. \n            Int. J. Cancer\n            , \n            87\n            , \n            336\n            \u2013342.","DOI":"10.1002\/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3"},{"key":"key\n\t\t\t\t20171012210115_B34","doi-asserted-by":"crossref","unstructured":"Weber,M.H., Lee,J. and Orr,F.W. (\n            2002\n            ) The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. \n            Int. J. Oncol.\n            , \n            20\n            , \n            299\n            \u2013303.","DOI":"10.3892\/ijo.20.2.299"},{"key":"key\n\t\t\t\t20171012210115_B35","unstructured":"Vaccari,M., Silingardi,P., Argnani,A., Horn,W., Giungi,M., Mascolo,M.G., Grilli,S. and Colacci,A. (\n            2000\n            ) \n            In vitro\n             effects of fenretinide on cell-matrix interactions. \n            Anticancer Res.\n            , \n            20\n            , \n            3059\n            \u20133066."},{"key":"key\n\t\t\t\t20171012210115_B36","doi-asserted-by":"crossref","unstructured":"Diel,I.J., Solomayer,E.F., Costa,S.D., Gollan,C., Goerner,R., Wallwiener,D., Kaufmann,M. and Bastert,G. (\n            1998\n            ) Reduction in new metastases in breast cancer with adjuvant clodronate treatment. \n            N. Engl. J. Med.\n            , \n            339\n            , \n            357\n            \u2013363.","DOI":"10.1056\/NEJM199808063390601"},{"key":"key\n\t\t\t\t20171012210115_B37","doi-asserted-by":"crossref","unstructured":"Powles,T., Paterson,S., Kanis,J.A. \n            et al\n            . (\n            2002\n            ) Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. \n            J. Clin. Oncol.\n            , \n            20\n            , \n            3219\n            \u20133224.","DOI":"10.1200\/JCO.2002.11.080"},{"key":"key\n\t\t\t\t20171012210115_B38","doi-asserted-by":"crossref","unstructured":"Diel,I.J., Solomyer,E.F. and Bastert,G. (\n            2000\n            ) Bisphosphonates and the prevention of metstases: first evidences from preclinical and clinical studies. \n            Cancer\n            , \n            88\n            , \n            3080\n            \u20133088.","DOI":"10.1002\/1097-0142(20000615)88:12+<3080::AID-CNCR27>3.0.CO;2-W"},{"key":"key\n\t\t\t\t20171012210115_B39","doi-asserted-by":"crossref","unstructured":"Saarto,T., Blomqvist,C., Virkkunen,P. and Elomaa,I. (\n            2001\n            ) Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. \n            J. Clin. Oncol.\n            , \n            19\n            , \n            10\n            \u201317.","DOI":"10.1200\/JCO.2001.19.1.10"}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/27\/3\/568\/7512823\/bgi233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T01:01:52Z","timestamp":1507856512000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/carcin\/article\/27\/3\/568\/2476115\/N4Hydroxyphenylretinamide-and-nitric-oxide"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9,30]]},"references-count":39,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2005,9,30]]},"published-print":{"date-parts":[[2006,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgi233","relation":{},"ISSN":["1460-2180","0143-3334"],"issn-type":[{"value":"1460-2180","type":"electronic"},{"value":"0143-3334","type":"print"}],"subject":[],"published-other":{"date-parts":[[2006,3]]},"published":{"date-parts":[[2005,9,30]]}}}